The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
The firm is offering access in Brazil to a digital assay that provides genomic insights using technology developed in a collaboration with computational pathology firm Paige.
Study investigators found that patients with ctDNA-positive results after surgery were at higher risk of bladder cancer recurrence than those who were ctDNA-negative.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
The firm said its test detects biomarkers inside monocyte blood cells that reflect the reduced clearance of amyloid beta (Aβ) plaque in the brain.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
The researchers have used nCounter, an FDA-cleared platform from NanoString Technologies, to develop their gene expression assay for subtype classification.
The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
Use of the Oncomine Focus Assay led to an expansion of genomic profiling for all guideline-recommend alterations and the identification of a broad set of clinically relevant targets.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.